Developer docs
API playgroundTry for free, no card

Search company profiles

Neon Therapeutics

Full company profile

uuid0006mrm

Namestring
Neon Therapeutics
Company typeenum
Private
Founded yearint
2015
Short descriptiontext

Neon Therapeutics was a clinical-stage biotech (founded 2015, Cambridge, MA) that developed personalized neoantigen cancer vaccines based on technology from Dana-Farber and the Broad Institute. Acquired by BioNTech in 2020, its platform was integrated into the iNeST pipeline.

Operating statusenum
Acquired
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersCambridge, United States
HQ citystring
Cambridge
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
neoantigen cancer vaccines, personalized immunotherapy, mRNA cancer treatment, oncology drug development, tumor mutation vaccines
Industry4 codes
PRIMARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
SECONDARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
SECONDARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAF
Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Cancer Immunotherapy
Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Neon Therapeutics developed a personalized neoantigen cancer vaccine platform that custom-designs therapeutic cancer vaccines based on individual tumor mutations using mRNA technology. The platform was originally developed at Dana-Farber Cancer Institute and the Broad Institute, and was acquired by BioNTech in 2020, with the technology integrated into BioNTech's iNeST pipeline. The platform is undergoing clinical trials for melanoma, head and neck cancers, and non-small cell lung cancer.

Differentiator
Functional benefit
Problem solved
Product and service1 record
1Personalized Neoantigen Cancer Vaccine Platform
Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

BioNTech acquired Neon Therapeutics in 2020 to advance the personalized neoantigen cancer vaccine platform. The technology, originally developed at Dana-Farber Cancer Institute and the Broad Institute, has been integrated into BioNTech's iNeST pipeline and is undergoing multiple clinical trials for melanoma, head and neck cancers, and non-small cell lung cancer. This acquisition represents a core strategic integration for BioNTech's cancer immunotherapy portfolio.

Peers10 records
TypeDirect peer
Description

CureVac develops mRNA-based cancer vaccines and therapeutics, including personalized neoantigen programs. It is a direct peer in mRNA cancer vaccine technology, though with broader infectious disease exposure.

TypeEmerging player
Description

Agenus develops immuno-oncology therapies including neoantigen vaccines and checkpoint antibodies. An emerging player with overlapping vaccine and combination strategy relevant to Neon's positioning.

TypeBroad incumbent
Description

Roche/Genentech is a broad immuno-oncology incumbent with Tecentriq and a pipeline of personalized cancer vaccine programs through partnerships. Comparable as a large incumbent pursuing neoantigen-based combinations.

TypeOthers
Description

Personalis provides genomic profiling and neoantigen identification services used to support personalized cancer vaccine design. It is an enabling technology peer that supports similar vaccine developers rather than a direct competitor.

5Transgene
TypeEmerging player
Description

Transgene develops individualized immunotherapy including TG4050, a personalized neoantigen vaccine using viral vector technology. Comparable emerging player in patient-specific cancer vaccines with a different delivery modality but similar targeting logic.

TypeEmerging player
Description

Genocea developed personalized neoantigen cancer vaccines (GEN-009) using a similar tumor-mutation-targeting approach. Comparable emerging player in personalized cancer immunotherapy, though smaller and earlier stage.

TypeDirect peer
Description

Moderna develops mRNA-4157, a leading personalized neoantigen cancer vaccine in late-stage melanoma trials with Merck. Comparable to Neon in using mRNA technology to encode patient-specific tumor neoantigens, and a direct competitor in the same product category.

TypeDirect peer
Description

Gritstone bio develops personalized neoantigen immunotherapies (SLATE and GRANITE programs) using a similar tumor-mutation-targeting approach. It is a direct competitor to Neon's platform in personalized cancer vaccine development.

TypeDirect peer
Description

BioNTech is Neon's parent company following the 2020 acquisition and the operator of the iNeST pipeline that integrates Neon's personalized neoantigen vaccine platform. BioNTech's internal FixVac and iNeST programs make it both the acquirer and the closest direct comparator in personalized cancer vaccines.

TypeBroad incumbent
Description

Merck's Keytruda (pembrolizumab) is the dominant checkpoint inhibitor used in combination with personalized neoantigen vaccines like Neon's. Broad incumbent in immuno-oncology and a strategic partner/competitor in the combination therapy market.

Market position
Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors12 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Neon Therapeutics

Cancer Immunotherapyneontherapeutics.com

Neon Therapeutics was a clinical-stage biotech (founded 2015, Cambridge, MA) that developed personalized neoantigen cancer vaccines based on technology from Dana-Farber and the Broad Institute. Acquired by BioNTech in 2020, its platform was integrated into the iNeST pipeline.

Neon Therapeutics firmographics

Firmographics
Name
Neon Therapeutics
Website
https://neontherapeutics.com
Company type
Private
Founded year
2015
Operating status
Acquired
Headcount range
51–100 employees
Short description
Neon Therapeutics was a clinical-stage biotech (founded 2015, Cambridge, MA) that developed personalized neoantigen cancer vaccines based on technology from Dana-Farber and the Broad Institute. Acquired by BioNTech in 2020, its platform was integrated into the iNeST pipeline.
Ownership category
akta.pro rank

Neon Therapeutics industry classification

Industry
Product category
Cancer Immunotherapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
SECONDARYHLAIAEAG
Therapeutic Vaccines (e.g., Cancer/Chronic Infection)
SECONDARYHLAAAEAB
Therapeutic Vaccines (cancer, chronic infection immunotherapy)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics
SECONDARYHLAAAEAF
Vaccine Delivery & Administration Systems (needle-free, microneedle patches, intranasal/oral)
Healthcare & Life Sciences/Biotechnology & Biologics/Vaccines & Immunization Biologics

Keywords

  • Neoantigen cancer vaccines
  • Personalized immunotherapy
  • MRNA cancer treatment
  • Oncology drug development
  • Tumor mutation vaccines

Where Neon Therapeutics is headquartered

Location

Headquarters

HQ city
Cambridge
HQ country
United States
HQ region
North America

Markets served

Neon Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Neon Therapeutics product offering

Product offering

Core offering

Neon Therapeutics developed a personalized neoantigen cancer vaccine platform that custom-designs therapeutic cancer vaccines based on individual tumor mutations using mRNA technology. The platform was originally developed at Dana-Farber Cancer Institute and the Broad Institute, and was acquired by BioNTech in 2020, with the technology integrated into BioNTech's iNeST pipeline. The platform is undergoing clinical trials for melanoma, head and neck cancers, and non-small cell lung cancer.

Differentiator

Problem solved

Functional benefit

Products and services

  • Personalized Neoantigen Cancer Vaccine Platform

Companies that use Neon Therapeutics

Customer profile

Ideal customer profiles2 records

Neon Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Neon Therapeutics partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • BioNTechcoreStrategic or Co-development Partner · 1 January 2020BioNTech acquired Neon Therapeutics in 2020 to advance the personalized neoantigen cancer vaccine platform. The technology, originally developed at Dana-Farber Cancer Institute and the Broad Institute, has been integrated into BioNTech's iNeST pipeline and is undergoing multiple clinical trials for melanoma, head and neck cancers, and non-small cell lung cancer. This acquisition represents a core strategic integration for BioNTech's cancer immunotherapy portfolio.

Neon Therapeutics competitors and assessment

Company assessment

Direct peers

  • CureVac: CureVac develops mRNA-based cancer vaccines and therapeutics, including personalized neoantigen programs. It is a direct peer in mRNA cancer vaccine technology, though with broader infectious disease exposure.
  • Moderna: Moderna develops mRNA-4157, a leading personalized neoantigen cancer vaccine in late-stage melanoma trials with Merck. Comparable to Neon in using mRNA technology to encode patient-specific tumor neoantigens, and a direct competitor in the same product category.
  • Gritstone bio: Gritstone bio develops personalized neoantigen immunotherapies (SLATE and GRANITE programs) using a similar tumor-mutation-targeting approach. It is a direct competitor to Neon's platform in personalized cancer vaccine development.
  • BioNTech: BioNTech is Neon's parent company following the 2020 acquisition and the operator of the iNeST pipeline that integrates Neon's personalized neoantigen vaccine platform. BioNTech's internal FixVac and iNeST programs make it both the acquirer and the closest direct comparator in personalized cancer vaccines.

Emerging players

  • Agenus: Agenus develops immuno-oncology therapies including neoantigen vaccines and checkpoint antibodies. An emerging player with overlapping vaccine and combination strategy relevant to Neon's positioning.
  • Transgene: Transgene develops individualized immunotherapy including TG4050, a personalized neoantigen vaccine using viral vector technology. Comparable emerging player in patient-specific cancer vaccines with a different delivery modality but similar targeting logic.
  • Genocea Biosciences: Genocea developed personalized neoantigen cancer vaccines (GEN-009) using a similar tumor-mutation-targeting approach. Comparable emerging player in personalized cancer immunotherapy, though smaller and earlier stage.

Broad incumbents

  • Genentech (Roche): Roche/Genentech is a broad immuno-oncology incumbent with Tecentriq and a pipeline of personalized cancer vaccine programs through partnerships. Comparable as a large incumbent pursuing neoantigen-based combinations.
  • Merck: Merck's Keytruda (pembrolizumab) is the dominant checkpoint inhibitor used in combination with personalized neoantigen vaccines like Neon's. Broad incumbent in immuno-oncology and a strategic partner/competitor in the combination therapy market.

Others

  • Personalis: Personalis provides genomic profiling and neoantigen identification services used to support personalized cancer vaccine design. It is an enabling technology peer that supports similar vaccine developers rather than a direct competitor.

Market position

Customer concentration

Neon Therapeutics social profiles

Digital presence

Neon Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Neon Therapeutics leadership team

Management profile

Number of profiles

Neon Therapeutics funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Neon Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neon Therapeutics

What does Neon Therapeutics do?

Neon Therapeutics developed a personalized neoantigen cancer vaccine platform that custom-designs therapeutic cancer vaccines based on individual tumor mutations using mRNA technology. The platform was originally developed at Dana-Farber Cancer Institute and the Broad Institute, and was acquired by BioNTech in 2020, with the technology integrated into BioNTech's iNeST pipeline. The platform is undergoing clinical trials for melanoma, head and neck cancers, and non-small cell lung cancer.

Is Neon Therapeutics a public or private company?

Neon Therapeutics is a private company. It is classified as corporate owned and is currently acquired.

When was Neon Therapeutics founded?

Neon Therapeutics was founded in 2015. It employs 51 to 100 people.

Where is Neon Therapeutics based?

Neon Therapeutics is headquartered in Cambridge, United States, in the North America region.

Who are Neon Therapeutics's main competitors?

Direct peers on record are CureVac, Moderna, Gritstone bio and BioNTech. Emerging players are Agenus, Transgene and Genocea Biosciences. Broad incumbents are Genentech (Roche) and Merck. Personalis is listed as an others.

Does Neon Therapeutics have an API?

No public API is recorded for Neon Therapeutics.

What industry is Neon Therapeutics in?

Neon Therapeutics's product category is Cancer Immunotherapy. Its primary akta.pro industry code is HLAAANAK, Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies), with a secondary code of HLAIAEAG, Therapeutic Vaccines (e.g., Cancer/Chronic Infection). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
BenzingaThe Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase PhNovartis received FDA approval for Tabrecta, a MET inhibitor for metastatic non-small cell lung cancer with specific mutations, while La Jolla Pharmaceutical submitted a competing acquisition offer for Tetraphase Pharmaceuticals. Additionally, PTC Therapeutics agreed to acquire Censa Pharmaceuticals and BioNTech closed its acquisition of Neon Therapeutics.PR NewswireFaruqi & Faruqi, LLP Announces Filing of a Class Action Lawsuit Against Neon Therapeutics, Inc. (NTGN)Faruqi & Faruqi, LLP filed a class action lawsuit in the U.S. District Court for the Southern District of New York against Neon Therapeutics, Inc. on behalf of shareholders who allege harm from violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934. The complaint concerns the proposed merger with BioNTech SE, alleging that the Form F-4 Registration Statement filed with the SEC contained materially incomplete and misleading information regarding the company's financial projections and analysis. The January 15, 2020 merger agreement offered Neon shareholders 0.063 American Depositary Shares of BioNTech for each share of Neon stock.PR NewswireSHAREHOLDER ALERT: WeissLaw LLP Investigates Neon Therapeutics, Inc.WeissLaw LLP has announced an investigation into Neon Therapeutics, Inc. regarding a proposed acquisition by BioNTech, examining whether the board fulfilled its fiduciary duty to maximize shareholder value. Under the deal terms, NTGN shareholders would receive 0.063 BioNTech American Depositary Shares per share of NTGN common stock, with NTGN merging into BNTX's wholly-owned subsidiary Endor Lights, Inc. The law firm noted that the average analyst target price for NTGN shares stands at $8.58, which exceeds the implied per-share value of the merger consideration, suggesting potential undervaluation of the company.PR NewswireBragar Eagel & Squire, P.C. Announces that it Is Investigating the Boards of Directors of Neon Therapeutics, Central Federal Bancshares, Franklin Financial Network, and Changyou.com Limited on behalfBragar Eagel & Squire, P.C. announced on January 24, 2020 that it is investigating potential stockholder claims regarding four separate acquisition/merger transactions involving Neon Therapeutics (being acquired by BioNTech for ~$67M), Central Federal Bancshares (being acquired by Southern Missouri Bancorp for ~$24M), Franklin Financial Network (merging with FB Financial), and Changyou.com Limited (merging with Sohu). The law firm stated it is examining whether the boards of directors of the target companies oversaw unfair processes and agreed to inadequate deal prices for their stockholders.PR NewswireMoore Kuehn, PLLC Encourages NTGN, HXL, FSB, and WMGI Investors to Contact FirmMoore Kuehn, PLLC, a New York-based securities law firm, announced investigations into four proposed mergers to determine whether they are fair to shareholders. The mergers involve Neon Therapeutics being acquired by BioNTech SE, Hexcel Corporation by Woodward, Inc., Franklin Financial Network by FB Financial Corporation, and Wright Medical Group by Stryker Corporation. The firm is soliciting affected shareholders to contact them regarding potential legal claims related to shareholder value and disclosure concerns.GlobesClal Biotech boosted by Neon saleClal Biotech, holding a 4% stake in Neon Therapeutics, saw its share price rise 1.03% after BioNTech agreed to acquire Neon at a $67 million valuation. The deal gives Neon shareholders 0.063 BioNTech shares per share, a 70% premium. Clal's market cap stood at NIS 203 million before trading.PR NewswirePrecision Medicine Market: Industry Analysis and Detailed Profiles of Neon Therapeutics, Moderna, Inc, Merck & Co., Inc, Bayer AG, PERSONALIS INC, GENOCEA BIOSCIENCES, INC | Data Bridge Market ResearcData Bridge Market Research published a report forecasting the global precision medicine market to grow with a substantial CAGR through 2026, driven by increasing cancer prevalence and regulatory approvals of personalized medicines. The study highlights key industry players such as Neon Therapeutics, Moderna, Merck & Co., Bayer AG, and BioNTech SE, noting their strategic activities in product launches and partnerships.FierceBiotechNeon Therapeutics' neoantigen vaccine boosts Opdivo response in 3 cancersNeon Therapeutics' personalized neoantigen vaccine combined with Opdivo prolonged progression-free survival in lung, bladder, and melanoma patients in a phase 1b study. The combination staved off cancer for a median of 5.6 months in 27 lung and 21 bladder patients, versus historical checkpoint inhibitor monotherapy data.FierceBiotechI-O startup Geneos raises $10.5M for neoantigen drugsGeneos Therapeutics, a spinout of Inovio Pharma, closed a $10.5 million Series A led by Santé Ventures and joined by Inovio. The funding will support its neoantigen-targeting cancer immunotherapy R&D, including first-in-human clinical trials. The company plans to complete IND activities for its first candidate.